Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
02 nov. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
27 oct. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
20 oct. 2022 18h15 HE
|
Jounce Therapeutics, Inc.
- Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 - - Two clinical posters highlighting data from the SELECT and INNATE trials at ESMO-IO - CAMBRIDGE,...
Jounce Therapeutics to Participate in the Upcoming Investor Conferences
07 sept. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients
30 août 2022 08h00 HE
|
Jounce Therapeutics, Inc.
- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in...
Jounce Therapeutics Reports Second Quarter 2022 Financial Results
04 août 2022 07h00 HE
|
Jounce Therapeutics, Inc.
- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - - Patient enrollment complete in the...
Jounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022
28 juil. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at Upcoming Investor Conferences
17 mai 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports First Quarter 2022 Financial Results
05 mai 2022 07h00 HE
|
Jounce Therapeutics, Inc.
- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022...
Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022
28 avr. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...